Results published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.
Find out moreOxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term…
Find out moreContract awarded for Breakthrough Technology: Bone Tissue Synthetic Implantable Products
Find out moreAward recognizes i-FACTOR™ Peptide Enhanced Bone Graft based on the company’s synthetic small peptide (P-15) technology
Find out moreFunds to support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft
Find out moreOrthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application
Find out moreOrthobiologics company has submitted response to remaining items from PMA review of i-FACTOR Peptide Enhanced Bone Graft
Find out moreCerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also a…
Find out moreResults published in International Journal of Spine Surgery
Find out more